{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:16Z","timestamp":1759336576859,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114034","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T19:51:46Z","timestamp":1638820306000},"page":"114034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier"],"prefix":"10.1016","volume":"229","author":[{"given":"Mennatallah","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-6992","authenticated-orcid":false,"given":"Mostafa M.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efseveia","family":"Frakolaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-0359","authenticated-orcid":false,"given":"Sotirios","family":"Katsamakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niki","family":"Vassilaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-9307","authenticated-orcid":false,"given":"Ralf","family":"Bartenschlager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-5186","authenticated-orcid":false,"given":"Grigoris","family":"Zoidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.H.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abdel-Halim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf H.","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2018","series-title":"PROGRESS REPORT ON ACCESS TO HEPATITIS C TREATMENT","author":"Countries","key":"10.1016\/j.ejmech.2021.114034_bib1"},{"key":"10.1016\/j.ejmech.2021.114034_bib2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.002","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","volume":"69","author":"Vermehren","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.114034_bib3","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejmech.2021.114034_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s15010-018-1188-3","article-title":"Resistance detection and re-treatment options in hepatitis C virus- related chronic liver diseases after DAA-treatment failure","volume":"46","author":"Sagnelli","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.ejmech.2021.114034_bib5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/jvh.12660","article-title":"Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: a systematic review","volume":"24","author":"Gimeno-Ballester","year":"2017","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.ejmech.2021.114034_bib6","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/liv.13383","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme","volume":"37","author":"H\u00e9zode","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.ejmech.2021.114034_bib7","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/apt.14592","article-title":"High efficacy of sofosbuvir\/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection","volume":"47","author":"Von Felden","year":"2018","journal-title":"Aliment. Pharmacol. The"},{"key":"10.1016\/j.ejmech.2021.114034_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.gastro.2014.06.021","article-title":"HCV NS5A inhibitors: the devil is in the details","volume":"147","author":"Elazar","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2021.114034_bib9","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1\u20137 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2021.114034_bib10","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: Implications for cross-genotype activity, Antimicrob","volume":"58","author":"Wang","year":"2014","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2021.114034_bib11","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1021\/acs.jmedchem.7b01927","article-title":"Discovery of MK-6169, a potent pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated substitutions","volume":"61","author":"Yu","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib12","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1021\/acs.jmedchem.8b00082","article-title":"Highlights of the structure-activity relationships of benzimidazole linked pyrrolidines leading to the discovery of the hepatitis C virus NS5A inhibitor pibrentasvir (ABT-530)","volume":"61","author":"Wagner","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib13","doi-asserted-by":"crossref","first-page":"10563","DOI":"10.1021\/acs.jmedchem.9b01562","article-title":"Discovery and characterization of potent pan-genotypic HCV NS5A inhibitors containing novel tricyclic central core leading to clinical candidate","volume":"62","author":"Ramdas","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib14","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/jm500335h","article-title":"Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect","volume":"57","author":"Belema","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib15","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1021\/acs.jmedchem.0c00530","article-title":"Amide bond bioisosteres: strategies, synthesis, and successes","volume":"63","author":"Kumari","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib16","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1016\/j.bmcl.2016.06.063","article-title":"Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors","volume":"26","author":"Dwyer","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114034_bib17","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.chembiol.2010.05.012","article-title":"Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology","volume":"17","author":"Thorne","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.114034_bib18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2174\/1568026616666151120113040","article-title":"A\u00a0comprehensive insight into the chemical space and ADME features of small molecule NS5A inhibitors","volume":"16","author":"Ivanenkov","year":"2016","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1021\/jm4016203","article-title":"Hepatitis C virus NS5A replication complex inhibitors. Part 6: discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons","volume":"57","author":"Belema","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejmech.2015.06.033","article-title":"Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors","volume":"101","author":"Bae","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1021\/acsinfecdis.6b00113","article-title":"A\u00a0comprehensive computational analysis for the binding modes of Hepatitis C virus NS5A inhibitors: the question of symmetry","volume":"2","author":"Ahmed","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.114034_bib22","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.02352-08","article-title":"Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus","volume":"83","author":"Love","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.114034_bib23","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","article-title":"Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication","volume":"147","author":"Berger","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2021.114034_bib24","article-title":"The discovery of conformationally constrained bicyclic peptidomimetics as potent hepatitis C NS5A inhibitors","volume":"13","author":"Kazmierski","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114034_bib25","first-page":"1","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Glob. Food Secur. Gov."},{"key":"10.1016\/j.ejmech.2021.114034_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance : update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2021.114034_bib27","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.3390\/v6114227","article-title":"Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding","volume":"6","author":"Issur","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ejmech.2021.114034_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2018.08.097","article-title":"Development of novel amide\u2013derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: identification of the cyclopropylamide moiety as a key modification","volume":"158","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114034_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5012\/bkcs.2003.24.4.407","article-title":"Efficient \u03b1-halogenation of carbonyl compounds by N-bromosuccinimide and N-chlorosuccinimde","volume":"24","author":"Lee","year":"2003","journal-title":"Bull. Kor. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114034_bib30","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1016\/j.bmcl.2014.10.056","article-title":"Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs","volume":"24","author":"Zhong","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114034_bib31","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1016\/j.bmcl.2014.10.057","article-title":"Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors","volume":"24","author":"Zhong","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114034_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0166-0934(03)00134-4","article-title":"A\u00a0replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C","volume":"110","author":"Vrolijk","year":"2003","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ejmech.2021.114034_bib33","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1053\/j.gastro.2008.12.034","article-title":"Analysis of CD8\u00a0+ T-cell \u2013 mediated inhibition of hepatitis C virus replication using a novel immunological model","volume":"136","author":"Jo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2021.114034_bib34","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1128\/AAC.01256-12","article-title":"Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells","volume":"56","author":"Saeed","year":"2012","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2021.114034_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1039\/C9MD00200F","article-title":"Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of: Flaviviridae viruses and Trypanosoma species","volume":"10","author":"Giannakopoulou","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2021.114034_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/cbdd.12966","article-title":"Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism","volume":"90","author":"Lougiakis","year":"2017","journal-title":"Chem. Biol. Drug Des"},{"key":"10.1016\/j.ejmech.2021.114034_bib37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/JVI.79.1.380-392.2005","article-title":"Kissing-loop interaction in the 3\u2032 End of the hepatitis C virus genome essential for RNA replication","volume":"79","author":"Friebe","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2021.114034_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2010","journal-title":"Gastroenterology,"},{"key":"10.1016\/j.ejmech.2021.114034_bib39","doi-asserted-by":"crossref","first-page":"13168","DOI":"10.1128\/JVI.01362-07","article-title":"Cell culture adaptation of hepatitis C virus and in\u00a0vivo viability of an adapted Variant","volume":"81","author":"Kaul","year":"2007","journal-title":"J.\u00a0Virol"},{"key":"10.1016\/j.ejmech.2021.114034_bib40","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1128\/JVI.01640-08","article-title":"Role of the hepatitis C virus core+1 open reading frame and core cis -acting RNA elements in viral RNA translation and replication","volume":"82","author":"Vassilaki","year":"2008","journal-title":"J.\u00a0Virol."},{"year":"1995","series-title":"Animal Cell Electroporation and Electrofusion Protocols","author":"Nickoloff","key":"10.1016\/j.ejmech.2021.114034_bib41"},{"key":"10.1016\/j.ejmech.2021.114034_bib42","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.bmcl.2012.02.051","article-title":"Inhibition of hepatitis C virus NS5A by fluoro-olefin based \u03b3-turn mimetics","volume":"22","author":"Chang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114034_bib43","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/ja00467a001","article-title":"Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms","volume":"99","author":"Allinger","year":"1977","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.114034_bib44","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.ejmech.2021.114034_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421008837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:35:12Z","timestamp":1759329312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421008837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":45,"alternative-id":["S0223523421008837"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114034","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114034"}}